

Akihiro Tsujimura appointed Executive Vice President and COO

The SanBio Group (SanBio Co., Ltd. and its subsidiary SanBio, Inc.) hereby announces that it has resolved to appoint Akihiro Tsujimura—current Senior Managing Director of SanBio Co., Ltd. and CEO of SanBio, Inc.—to the position of Executive Vice President and Chief Operating Officer (COO), effective September 15, 2020 (September 14, 2020, US time) for the development of the Group as a whole.

Mr. Tsujimura accumulated diverse experience in corporate management while working at Nichimen Corp. (current Sojitsu Corp.), through his involvement in various operations ranging from the establishment and management of overseas businesses to corporate turnarounds in Japan. At Santen Pharmaceutical Co., Ltd., he gained a wealth of experience in pharmaceutical business operations, including business development, M&A, and overseas expansion. The SanBio Group expects Mr. Tsujimura to draw on his experience and track record in corporate management to make further contributions to the Group’s global expansion. He will maintain his position of CEO at SanBio, Inc., the Company’s U.S. subsidiary.

Currently, the SanBio Group is working toward filing for manufacture and marketing approval of SB623 as a regenerative medicine product for the treatment of chronic motor deficit from traumatic brain injury (TBI) in Japan by the end of the fiscal year ending January 2021 (February 2020–January 2021). As the new Vice President and COO of the Company, Mr. Tsujimura will oversee the entire operation of the Group, including making necessary preparations to launch SB623 as a therapeutic drug for the treatment of chronic effects resulting from TBI in Japan and in other countries thereafter (i.e., global development of the product), as well as preparations to resume clinical trials in the ischemic stroke program. Under his leadership, we will aim to maximize the value of SB623 and continue considering various development options, including in-house development and entering partnerships.

Mr. Tsujimura commented as below in regard to his new position:

“Ever since I joined the Company in October 2018, together with top management led by President Mori, as well as our members in Japan and the U.S., I worked to maximize the value of SB623 and also of SanBio. With the mission to deliver SB623 to patients as soon as possible, I take my appointment to the position of Vice President and COO seriously, and I will do my utmost to take SanBio to the next phase of growth.”

Representative Director and President Mori commented as follows:

“Since our founding in 2001, we have worked to develop new drugs in the novel field of regenerative cell

medicine to contribute to improving the lives of patients facing difficulties, as well as of their family members. Amid numerous challenges we encountered as we navigated through the completely new field of drug development, Mr. Tsujimura, as CEO of the Company's U.S. subsidiary SanBio, Inc. and as a member of management of the SanBio Group aiming to become a global leader, has demonstrated outstanding leadership and established strong presence both in and outside the Company. As SanBio transitions to a new phase, we expect him to make greater contributions to its development from his new post."

About SanBio Co., Ltd. and SanBio, Inc.

SanBio Group is engaged in the regenerative cell medicine business, spanning research, development, manufacture, and sales of regenerative cell medicines. The Company's propriety regenerative cell medicine product, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from traumatic brain injury and ischemic stroke. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at <https://sanbio.com>.

For more information, contact:

SanBio Co., Ltd.

Management Administration

info@sanbio.jp